Aptevo Therapeutics (APVO) said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.
The company said nine of ten frontline patients across two studies have now reached remission with the triplet combination of mipletamig, venetoclax, and azacitidine.
Cohort 2 of the trial is nearly fully enrolled, with patients receiving the same dose used in an earlier expansion study, Aptevo said, adding that one patient in the latest cohort progressed and died from causes unrelated to the treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。